| Safety, activity, and immune correlates of anti–PD-1 antibody in cancer SL Topalian, FS Hodi, JR Brahmer, SN Gettinger, DC Smith, ... New England Journal of Medicine 366 (26), 2443-2454, 2012 | 14427 | 2012 |
| PD-1 blockade in tumors with mismatch-repair deficiency DT Le, JN Uram, H Wang, BR Bartlett, H Kemberling, AD Eyring, ... New England Journal of Medicine 372 (26), 2509-2520, 2015 | 10216 | 2015 |
| Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade DT Le, JN Durham, KN Smith, H Wang, BR Bartlett, LK Aulakh, S Lu, ... Science 357 (6349), 409-413, 2017 | 6641 | 2017 |
| Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates JR Brahmer, CG Drake, I Wollner, JD Powderly, J Picus, WH Sharfman, ... Journal of clinical oncology 28 (19), 3167-3175, 2010 | 3712 | 2010 |
| Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab SL Topalian, M Sznol, DF McDermott, HM Kluger, RD Carvajal, ... Journal of clinical oncology 32 (10), 1020-1030, 2014 | 2782 | 2014 |
| Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy SL Topalian, JM Taube, RA Anders, DM Pardoll Nature Reviews Cancer 16 (5), 275-287, 2016 | 2759 | 2016 |
| Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti–PD-1 therapy JM Taube, A Klein, JR Brahmer, H Xu, X Pan, JH Kim, L Chen, DM Pardoll, ... Clinical cancer research 20 (19), 5064-5074, 2014 | 2638 | 2014 |
| Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape JM Taube, RA Anders, GD Young, H Xu, R Sharma, TL McMiller, S Chen, ... Science translational medicine 4 (127), 127ra37-127ra37, 2012 | 2484 | 2012 |
| Fulminant myocarditis with combination immune checkpoint blockade DB Johnson, JM Balko, ML Compton, S Chalkias, J Gorham, Y Xu, ... New England Journal of Medicine 375 (18), 1749-1755, 2016 | 2199 | 2016 |
| Neoadjuvant PD-1 blockade in resectable lung cancer PM Forde, JE Chaft, KN Smith, V Anagnostou, TR Cottrell, MD Hellmann, ... New England Journal of Medicine 378 (21), 1976-1986, 2018 | 2125 | 2018 |
| Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer PM Forde, J Spicer, S Lu, M Provencio, T Mitsudomi, MM Awad, E Felip, ... New England Journal of Medicine 386 (21), 1973-1985, 2022 | 1890 | 2022 |
| The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints NJ Llosa, M Cruise, A Tam, EC Wicks, EM Hechenbleikner, JM Taube, ... Cancer discovery 5 (1), 43-51, 2015 | 1588 | 2015 |
| PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma PT Nghiem, S Bhatia, EJ Lipson, RR Kudchadkar, NJ Miller, L Annamalai, ... New England Journal of Medicine 374 (26), 2542-2552, 2016 | 1377 | 2016 |
| Evidence for a role of the PD-1: PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma S Lyford-Pike, S Peng, GD Young, JM Taube, WH Westra, B Akpeng, ... Cancer research 73 (6), 1733-1741, 2013 | 862 | 2013 |
| Neoadjuvant checkpoint blockade for cancer immunotherapy SL Topalian, JM Taube, DM Pardoll Science 367 (6477), eaax0182, 2020 | 837 | 2020 |
| A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non–small cell lung cancer DL Rimm, G Han, JM Taube, SY Eunhee, JA Bridge, DB Flieder, R Homer, ... JAMA oncology 3 (8), 1051-1058, 2017 | 788 | 2017 |
| Control of PD-L1 expression by oncogenic activation of the AKT–mTOR pathway in non–small cell lung cancer KJ Lastwika, W Wilson III, QK Li, J Norris, H Xu, SR Ghazarian, ... Cancer research 76 (2), 227-238, 2016 | 784 | 2016 |
| Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody EJ Lipson, WH Sharfman, CG Drake, I Wollner, JM Taube, RA Anders, ... Clinical Cancer Research 19 (2), 462-468, 2013 | 676 | 2013 |
| Pd-1/pd-l1 inhibitors J Sunshine, JM Taube Current opinion in pharmacology 23, 32-38, 2015 | 658 | 2015 |
| Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes CM Heaphy, AP Subhawong, SM Hong, MG Goggins, EA Montgomery, ... The American journal of pathology 179 (4), 1608-1615, 2011 | 611 | 2011 |
